Sage Mountain Advisors’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Sage Mountain Advisors’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-86,890	Closed	-$860K	–	552
2022 Q2	$860K	Sell	86,890 -7,750	-8%	-$77K	0.15%	115
2022 Q1	$933K	Sell	94,640 -2,000	-2%	-$19.8K	0.15%	122
2021 Q4	$964K	Sell	96,640 -1,980	-2%	-$19.9K	0.12%	147
2021 Q3	$977K	Buy	98,620 +2,650	+3%	+$26.5K	0.14%	130
2021 Q2	$979K	Hold	95,970	–	–	0.16%	116
2021 Q1	$965K	Hold	95,970	–	–	0.21%	82
2020 Q4	$1.02M	Buy	+95,970	New	+$975K	0.33%	46

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Sage Mountain Advisors's EUCRU Position: Q3 2022 in Review

Sage Mountain Advisors sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q3 2022, closing a stake of 86,890 shares — an estimated $860K sold.

Sage Mountain Advisors first reported a position in EUCRU in Q4 2020 and held it in 7 quarters. The position peaked at $1.02M in Q4 2020. 13 funds tracked by Wall St. Rank hold EUCRU as of Q3 2022.

Sage Mountain Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q3 2022 after selling out during the quarter.
Sage Mountain Advisors sold 86,890 Eucrates Biomedical Acquisition Corp. Unit shares in Q3 2022, an estimated $860K.
Sage Mountain Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 7 quarters.
Sage Mountain Advisors's Eucrates Biomedical Acquisition Corp. Unit position peaked at $1.02M in Q4 2020.
13 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q3 2022.

Based on Sage Mountain Advisors's 13F filing for Q3 2022, filed 31 Oct 2022.